Jeffrey H. Perry


Jeff Perry
Jeff Perry, a partner in the Washington, D.C. office, focuses on antitrust investigations and litigation, with an emphasis on mergers and acquisitions. A highly recognized leader in the field, Jeff is lead antitrust counsel to a number of Fortune 50 clients. Prior to private practice, he served for 13 years at the Federal Trade Commission, most recently as Assistant Director of the Federal Trade Commission’s Bureau of Competition.

Jeff is a veteran antitrust enforcer and practitioner. During his tenure at the FTC, Jeff led and managed hundreds of significant merger matters, including investigations and challenges across virtually every industry overseen by the agency. As Assistant Director, Jeff headed the FTC’s Mergers IV Division, which oversees federal antitrust enforcement in a variety of industries, including supermarkets, retail stores, hospitals and other healthcare providers, food and beverage products, casinos, and a wide range of consumer products. He had leading roles in numerous high-profile investigations and litigations, including Office Depot/OfficeMax, ProMedica/St. Luke’s, OSF/Rockford MemorialKroger/Harris Teeter, Phoebe Putney/Palmyra, Pinnacle/AmeristarReading Hospital/Surgical Institute of Reading, and Whole Foods/Wild Oats. Jeff also worked closely with senior antitrust enforcement officials in several countries and State Attorneys General offices.

Prior to becoming Assistant Director, Jeff served in a number of important government positions, including Special Assistant United States Attorney in the District of Columbia, where he first-chaired more than 20 criminal trials, and Counsel to the Director of the Bureau of Competition at the FTC, where he oversaw merger and non-merger cases across a range of industries. Before being promoted to Assistant Director, he served as Deputy Assistant Director of the Bureau of Competition.

Jeff is recommended for Merger Control by Legal 500 US and recognized for Antitrust in Washington, D.C. by Chambers USA, where clients note he is “a highly effective antitrust lawyer who gives excellent practice advice to clients,” and “extremely talented, knowledgeable and a great communicator.” Global Competition Review recognizes Jeff as a leading competition lawyer in its worldwide guide, Who’s Who Legal Competition 2020 and he is also named by Legal Media Group as one of the “Top 30 Competition and Antitrust Practitioners in the U.S.” in its 2020 edition of Best of the Best USA Expert Guides. Jeff is also recognized as a top antitrust lawyer in the Best Lawyers in America guide. In 2017, Jeff was selected as an Antitrust “Trailblazer” by The National Law Journal. He was also recognized by The National Law Journal in 2014as one of the “D.C. Rising Stars” — a list of 40 “game-changing” private, government and public interest advocacy attorneys aged 40 or under practicing in Washington, D.C.

Jeff is a regular lecturer on antitrust and business topics at The Antonin Scalia Law School and The Wharton School of the University of Pennsylvania. In addition, Jeff is an active member of the antitrust bar and has served in various leadership positions of the Antitrust Section of the ABA, including as Vice Chair of the Pricing Conduct Committee.

Representative Matters

  • Johnson & Johnson in its proposed ~$16.6 billion acquisition of heart pump maker Abiomed Inc.
  • Johnson & Johnson and DePuy Synthes in the acquisition of orthopedic company CrossRoads Extremity Systems.
  • C&S Wholesale Grocers in connection with the Federal Trade Commission’s study under Section 6(b) of the FTC Act regarding the competitive impact of supply chain disruptions in consumer goods.
  • 365 Retail Markets, a provider of self-service technologies and vending offerings, in its merger with Avanti Markets.
  • ZoomInfo Technologies in its acquisition of, a provider of conversational intelligence solutions.
  • Core-Mark Holding Company, a wholesale distributor to the convenience retail industry, in its $2.5 billion sale to Performance Food Group.
  • Ambassador Theatre Group in its acquisition of touring Broadway show theaters in San Francisco and Detroit.
  • Meta (f/k/a Facebook) in its acquisition of Kustomer, a customer relationship management (CRM) company.
  • TopGolf in its $2 billion merger of equals with Callaway Golf Company.
  • CoStar Group in the antitrust aspects of its acquisition of Ten-X’s commercial real estate transaction platform.
  • Fairway Group Holdings, an iconic New York supermarket chain, in the antitrust aspects of its chapter 11 cases.
  • Willis Towers Watson PLC in the antitrust aspects of its proposed $80 billion combination with Aon PLC.
  • Enverus in the antitrust aspects of its acquisition of RS Energy Group, a technology firm focused in the upstream oil & gas industry.
  • Varian Medical Systems, Inc. in the antitrust aspects of its $90 million acquisition of interventional oncology assets from Boston Scientific.
  • Willis Towers Watson in the $1.2 billion acquisition of TRANZACT, a direct-to-consumer health care organization that links individuals to U.S. insurance carriers.
  • Belmond Ltd., an owner and operator of luxury hotels, tourist trains, a river cruise ship and restaurants, in the antitrust aspects of its pending $3.2 billion sale to LVMH Moet Hennessy Louis Vuitton SE.
  • Nexeo Solutions, Inc. in the antitrust aspects of its $2 billion sale to Univar Inc.
  • BASF in its $11B acquisition of seed and herbicide businesses and assets pursuant to a DOJ antitrust consent decree in connection with Bayer’s acquisition of Monsanto. At the time, BASF’s acquisition was the largest negotiated merger divestiture in the history of US antitrust enforcement.
  • Bridgestone Americas in its joint venture with Goodyear to form a national tire distributor.
  • CoStar Group, owner of, in the antitrust aspects of its $385 million acquisition of online apartment rental platform
  • Walgreens Boots Alliance in its acquisition of 1,932 Rite Aid stores and related assets, a transaction valued at $4.377 billion.
  • DiscoverOrg and its PE sponsor TA Associates on the antitrust aspects of its acquisition of RainKing from Spectrum Equity.
  • G & K Services, Inc. in its $2.2 billion merger with Cintas Corporation. Although the deal received a Second Request, it obtained unconditional clearance from the U.S. Federal Trade Commission.
  • Dean Foods in its acquisition of Friendly’s ice cream manufacturing and distribution business.
  • WEX Inc., a leading provider of corporate payment solutions, in its $1.5 billion acquisition of Electronic Funds Source LLC. The deal received unconditional clearance from the U.S. Federal Trade Commission despite the issuance of a Second Request.
  • The Great Atlantic & Pacific Tea Company, Inc. (A&P) in its chapter 11 case. As part of the chapter 11 plan, A&P sought to sell 120 stores to supermarket competitors, including Albertsons, Royal Ahold, and Key Food Stores. Weil secured prompt antitrust clearance from the FTC for the sale of A&P’s stores, relying in part on the rarely-successful failing firm defense.
  • Willis Group Holdings in its merger with Towers Watson, a transaction valued at approximately $18 billion. The combined company will be named Willis Towers Watson and will create an integrated global advisory, brokering and solutions provider with approximately 39,000 employees in over 120 countries.

Awards and Recognition, Speaking Engagements, Latest Thinking, Firm News & Announcements

Awards and Recognition

Speaking Engagements

View all

Latest Thinking

Firm News & Announcements

View all